文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

离体γH2AX检测评估初治前列腺癌患者肿瘤放射敏感性及其与临床参数的相关性

Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters.
PubMed 文献 · Radiat Oncol · 2022-10-05

研究纳入21例病理证实的前列腺癌患者,对26个癌灶活检标本行离体照射(0和4 Gy)后24小时计数残余γH2AX焦点作为放射抵抗替代指标。最终分析16例患者18个癌灶,中位γH2AX焦点值3.12,据此分组后放射敏感组PSA血清浓度、PSMA PET的SUVmax和SUVmean更高而ADCmean更低,均与放射抵抗相关。

要点

  • 离体γH2AX焦点计数可用于评估前列腺癌灶间放射抵抗异质性。
  • 放射敏感组PSA血清浓度显著更高(p=0.015)。
  • 放射敏感组肿瘤区SUVmax和SUVmean更高、ADCmean更低。

核心结论

  • 在这项先导研究中观察到肿瘤间放射抵抗存在显著差异,临床和影像参数或可用于其预测。
  • 作者认为,经更大患者队列进一步前瞻性验证后,这些发现未来可能指导前列腺癌患者的个体化放疗剂量处方。

研究设计与样本

  • 研究纳入21例组织学证实的前列腺癌患者,均具有治疗前多参数磁共振成像和前列腺特异性膜抗原正电子发射断层扫描。
  • 从26个前列腺癌灶采集活检标本,离体照射(0和4 Gy)后24小时计数残余γH2AX焦点作为放射抵抗的替代指标。
  • 收集临床、基因组(下一代测序)和影像特征,研究其与放射抵抗的关联;最终分析纳入16例患者的18个前列腺癌病灶。

主要发现

  • 每个前列腺癌病灶的中位γH2AX焦点值为3.12,据此将患者分为放射敏感组与放射抵抗组,两组焦点数差异显著(p < 0.0001)。
  • 放射敏感组患者的前列腺特异性抗原血清浓度显著更高(p = 0.015)。
  • 放射敏感组肿瘤区的PSMA PET SUVmax和SUVmean更高(p = 0.0037,p = 0.028),ADCmean更低(p = 0.049)。
  • 上述参数在Pearson检验中均具有显著相关性(p < 0.05)。
  • 放射敏感组中1例患者携带既往未报道的NBN基因功能丧失移码突变(c.654_658delAAAAC),该突变引入提前终止密码子并导致截短蛋白。

局限性

  • 原文结论指出,这些发现需在更大患者队列中进一步前瞻性验证。
  • 原文将该研究定性为先导研究(pilot study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKROUND: Accurate surrogate parameters for radio resistance are warranted for individualized radiotherapy (RT) concepts in prostate cancer (PCa). The purpose of this study was to assess intertumoral heterogeneity in terms of radio resistance using an ex-vivo γH2AX assay after irradiation of prostate biopsy cores and to investigate its correlation with clinical features of respective patients as well as imaging and genomic features of tumor areas. METHODS: Twenty one patients with histologically-proven PCa and pre-therapeutic multiparametric resonance imaging and prostate-specific membrane antigen positron emission tomography were included in the study. Biopsy cores were collected from 26 PCa foci. Residual γH2AX foci were counted 24 h after ex-vivo irradiation (with 0 and 4 Gy) of biopsy specimen and served as a surrogate for radio resistance. Clinical, genomic (next generation sequencing) and imaging features were collected and their association with the radio resistance was studied. RESULTS: In total 18 PCa lesions from 16 patients were included in the final analysis. The median γH2AX foci value per PCa lesion was 3.12. According to this, the patients were divided into two groups (radio sensitive vs. radio resistant) with significant differences in foci number (p < 0.0001). The patients in the radio sensitive group had significantly higher prostate specific antigen serum concentration (p = 0.015), tumor areas in the radio sensitive group had higher SUV (standardized uptake values in PSMA PET)-max and -mean values (p = 0.0037, p = 0.028) and lower ADC (apparent diffusion coefficient-mean values, p = 0.049). All later parameters had significant (p < 0.05) correlations in Pearson's test. One patient in the radio sensitive group displayed a previously not reported loss of function frameshift mutation in the NBN gene (c.654_658delAAAAC) that introduces a premature termination codon and results in a truncated protein. CONCLUSION: In this pilot study, significant differences in intertumoral radio resistance were observed and clinical as well as imaging parameters may be applied for their prediction. After further prospective validation in larger patient cohorts these finding may lead to individual RT dose prescription for PCa patients in the future.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Marinescu IM, Rogg M, Spohn S, et al. Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters. Radiat Oncol. 2022. PMID: 36199143. doi:10.1186/s13014-022-02131-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。